The Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) drugs in development market research report provides comprehensive information on the therapeutics under development for Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) by seven companies/universities/institutes. The top development phase for Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) is preclinical with four drugs in that stage. The Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) pipeline has seven drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) pipeline products market are: RegenxBio, ReqMed and Hanmi Pharmaceuticals.
The key targets in the Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) pipeline products market include Arylsulfatase B (N Acetylgalactosamine 4 Sulfatase or ASB or ARSB or EC 3.1.6.12), A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.), and A Disintegrin And Metalloproteinase With Thrombospondin Motifs 4 (ADMP1 or Aggrecanase 1 or ADAMTS4 or EC 3.4.24.82).
The key mechanisms of action in the Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) pipeline product include Arylsulfatase B (N Acetylgalactosamine 4 Sulfatase or ASB or ARSB or EC 3.1.6.12) Activator with two drugs in Phase II. The Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) pipeline products include four routes of administration with the top ROA being Subcutaneous and five key molecule types in the Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) pipeline products market including Polysaccharide, and Recombinant Enzyme.
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) overview
Mucopolysaccharidosis type VI (MPS VI), also known as Maroteaux-Lamy syndrome, is a progressive condition that causes many tissues and organs to enlarge, become inflamed or scarred, and eventually waste away (atrophy). Skeletal abnormalities are also common in this condition. The rate at which symptoms worsen varies among affected individuals
For a complete picture of Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome )’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
